Therefore, we deemed that our asthma model was appropriate for testing the in vivo anti-asthmatic efficacy of IGF1R inhibition using the IGF1R TKI inhibitor NVP-ADW742 (NVP). The gene discussed is IGF1R; the disease is asthma.